Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
Teva Pharmaceutical Industries Ltd.(NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completio…
Teva Pharmaceutical Industries Ltd.(NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced completio…
Ypsomed benefits from the growth dynamics in drug self-administration, diabetes and insulin. Ypsomed has made a very goo…
The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an impor…
Nanotechnology has definitely arrived in the world of commercial applica-tions. An increasing number of businesses are u…
. - Total revenues of the Ypsomed group grew by 3.6% to CHF 287.5 million (previous year CHF 277.5 million) - Gross pr…